Nevirapine in the treatment of HIV. - Wikidata - awgldk - TriplyDB

Nevirapine in the treatment of HIV.

Nevirapine in the treatment of HIV.

http://www.wikidata.org/entity/Q35917412

about

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.QbD-oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid-liquid extraction and chromatographic separation.A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.Clinical and genetic determinants of nevirapine plasma trough concentration.Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

P2860

Q24811445-D7AAB8D6-761C-408B-AFCE-87D712656CE7 Q27663609-D5861E76-3E79-4293-AF13-0FA263A83DE9 Q33277939-67917A36-2868-4F93-8240-0398A4EB70C7 Q35767808-5D9B4A5B-077E-4DE4-B95B-122ED3E9A0BD Q35827891-607C4AAB-9A10-429C-A9FC-70E4FA0B3476 Q35859896-6D38071B-984F-49FB-B6C7-69D5D36F3C01 Q36024652-BEA2529F-6C3C-41F3-A190-73CEA2845428 Q36276839-0010C4A6-01AF-407D-93F2-6DDA58A8E79C Q37509532-D5FC925F-A446-4A00-ABC3-E98E537DA781 Q39692280-192CEC3F-641C-47D9-A9C1-FBCD3019ED1D Q46923095-C81220B9-2A6C-4763-A949-6DEDF2440784 Q51008407-0ED0CCC9-77AE-4824-8F69-0B6B1EFA3D83 Q55263551-9322E301-2B09-4870-94AC-430A2E21E703 Q59136209-787A7198-AF8F-42C6-9362-81B4A94C7E8F

P2860

Nevirapine in the treatment of HIV.

http://www.wikidata.org/entity/Q35917412

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Nevirapine in the treatment of HIV.

@ast

Nevirapine in the treatment of HIV.

@en

type

label

Nevirapine in the treatment of HIV.

@ast

Nevirapine in the treatment of HIV.

@en

prefLabel

Nevirapine in the treatment of HIV.

@ast

Nevirapine in the treatment of HIV.

@en

P1433

Q35917412-B879C5AD-BC4A-41F6-89A9-2DD402203FB7

P1476

Q35917412-9DA739BE-B36C-42C3-B1CF-D97B64190EEB

P2093

Q35917412-28F3FE1D-E110-4F7C-9C49-3B2F788D6898

P2860

Q35917412-033359F0-F127-4846-9645-A071EED25EA6

Q35917412-1402DDE9-7AC3-4C46-BF7F-B9DC47EBC182

Q35917412-15EAF83E-A593-4292-B1FA-839BB48089D3

Q35917412-2915AB6A-189A-4DEA-A018-81ADD37F3594

Q35917412-30AB1528-C937-4279-A45D-CBE48E08A877

Q35917412-351E31CE-39FA-4754-8601-1902C99D62E0

Q35917412-3A1E4382-2EC1-48E6-B7EE-5BA264B13921

Q35917412-3AD36447-849E-48DC-82D5-E1397F91828A

Q35917412-40E74489-60DA-4A93-A450-FC550D12EE21

Q35917412-4BF56EC7-4737-48CD-ABF1-894514B2BE88

P304

Q35917412-6A5F6D17-6FC9-4771-AA10-2397F5DCE80B

P31

Q35917412-72DB70EB-6428-4A54-A88B-325024447099

P356

Q35917412-8A8BD01B-5804-413E-AEFD-187D26108A9D

P433

Q35917412-9D2613D1-490F-413A-BCCC-5CDBE8A98986

P478

Q35917412-DA2426A8-C15B-477E-AD30-E604C8AAB35F

P50

Q35917412-B829B5EE-7879-4A08-9F42-A934F1E52304

P577

Q35917412-18607565-1B69-4A05-8D77-D5E3C38F4FEF

P698

Q35917412-1D8F8C83-0797-421D-9D7C-07E2545EB99F

P356

14787210.2.3.367

P1433

Expert Review of Anti-infective Therapy

P1476

Nevirapine in the treatment of HIV.

@en

P2093

Esteban Martínez

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.

Impact of nevirapine on lipid metabolism.

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

P304

367-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.2.3.367

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15482202

http://www.w3.org/2001/XMLSchema#string